Molecular Diagnostics Platforms Patent Landscape Analysis Report 2026 Edition

Molecular Diagnostics Platforms Market Size, Growth Trends, and Industry Outlook

Molecular diagnostics platforms combine sample preparation, nucleic acid amplification or sequencing, detection and result reporting in integrated instruments and consumables. Demand spans central laboratory analysers that process thousands of samples a day and compact cartridge systems placed close to the patient. Infectious disease testing anchors volume, while oncology, inherited disease and transplant monitoring add higher-value assays on the same installed instruments. Each placed instrument creates a recurring stream of assay sales, which keeps vendors focused on platform design.

Market growth is driven by the move of respiratory and sexually transmitted infection testing to sample-to-answer systems that report results in under an hour. In January 2025 FDA granted 510(k) clearance with CLIA waiver to the Roche cobas Liat chlamydia, gonorrhoea and Mycoplasma genitalium panels, which extends molecular testing to clinics and pharmacies.

The World Health Organisation reported that about 10.8 million people fell ill with tuberculosis in 2023, and its guidance names rapid molecular tests as the first diagnostic, which sustains orders for cartridge systems in high-burden countries. In high-income markets, primary HPV screening is moving to molecular testing, and FDA approved self-collection with Roche cobas HPV in May 2024, which widens the sample base for central laboratories. The court decision of March 2025 that vacated FDA's laboratory developed test rule keeps laboratory-built assays running on open platforms, so instruments that accept custom reagents hold their demand.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Molecular Diagnostics Platforms Patent Filing Trends and Innovation Activity

Molecular diagnostics platforms attract filings from diagnostic majors, life science tool makers, microfluidics start-ups and university spin-outs. Claims concentrate on cartridge fluidics, extraction chemistry, multiplex primer design, thermal cycling hardware and data analysis software.

The dataset contains more than 14,500 patent families, with filing activity peaking between 2020 and 2023. Pandemic-era demand for high-throughput and near-patient testing explains the surge, and sequencing-based assays kept filings high after 2022.

Rising demand for rapid, multiplex and decentralised testing has translated directly into patent filings on cartridge architecture, extraction automation and panel chemistry.

Scope of the Molecular Diagnostics Platforms Patent Landscape Analysis Report

The report covers patents on automated extraction systems, real-time and digital PCR instruments, isothermal amplification devices, microfluidic sample-to-answer cartridges, multiplex syndromic panel platforms and sequencing workstations used for clinical diagnosis. Reagent kits are included where claims are tied to a platform architecture.

Software claims on result interpretation, instrument connectivity and laboratory informatics fall inside the scope. Research-only sequencers and standalone assay patents without platform claims are excluded.

Assignees analysed include diagnostic and life science companies, microfluidics and point-of-care start-ups, universities and research institutes, and hospital groups holding granted patents and pending applications.

Global Molecular Diagnostics Platforms Patent Landscape Analysis

Molecular Diagnostics Platforms Patent Filing Trend Analysis

Annual patent filings for molecular diagnostics platforms grew at an estimated 6 to 8 percent per year between 2020 and 2024. Pandemic testing programmes, lower-cost microfluidic fabrication and clinical uptake of sequencing assays drove this increase.

Grants in 2025 exceeded 1,900, with a rising share covering cartridge-based multiplex systems and sequencing workflows. Publication lags of 18 months mean that filings from 2025 and 2026 continue to enter the data.

Leading Companies and Assignee Analysis in the Molecular Diagnostics Platforms Patent Landscape

Geographic Analysis of Molecular Diagnostics Platforms Patent Activity

The report assesses patent activity across major jurisdictions, including:

• United States
• Europe
• China
• Japan
• South Korea
• India
• International and WIPO filings

The United States records the largest volume of filings and grants, supported by a large installed base of laboratory analysers and a deep reimbursement system. China ranks second, with domestic instrument makers and universities filing at high rates since 2020. Europe follows, with filings tied to CE-marked assays and the transition to the In Vitro Diagnostic Regulation.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Molecular Diagnostics Platforms Technology Segmentation and Innovation Areas

The report segments patent activity by technology, application and platform format, with the following technology segments covered:

• Real-time PCR
• Digital PCR
• Isothermal Amplification
• Sequencing-based Detection
• Microarray and Hybridisation

Among these, real-time PCR holds the largest share of patent families because it underlies most high-throughput analysers and cartridge systems.

Competitive Landscape and Emerging Trends in the Molecular Diagnostics Platforms Market

Competition centres on installed instrument base, assay menu breadth and cartridge manufacturing scale. Roche and Abbott lead in central laboratory analysers, Danaher leads in cartridge-based systems, and Thermo Fisher Scientific and Illumina lead in sequencing-based diagnostics. Start-ups with microfluidic and isothermal designs file in niches such as at-home sexually transmitted infection testing.

Companies are focusing on:

• Sample-to-answer cartridge fluidics
• Automated nucleic acid extraction
• Multiplex syndromic panel design
• Isothermal amplification at the point of care
• Digital PCR quantification
• Clinical sequencing workflows
• Laboratory informatics and instrument connectivity

Emerging innovation themes include home-use molecular tests following the 2025 De Novo authorisation of an at-home chlamydia, gonorrhoea and trichomonas test, long-read and sequencing by expansion chemistries for clinical use, and digital PCR for minimal residual disease monitoring. Machine-learning interpretation of amplification curves and CRISPR-based detection modules add further filing activity.

Strategic Insights from the Molecular Diagnostics Platforms Patent Landscape

The landscape combines mature PCR instrument families with fast-moving cartridge, sequencing and home-testing portfolios. Large assignees defend installed bases through continuation families, while start-ups seek licensing or acquisition after regulatory clearance. Hologic's 2025 agreement to be acquired by two private equity investors and Abbott's agreement for Exact Sciences show that platform portfolios attract active deal flow.

Technology segments, application areas and platform formats are tracked across jurisdictions and assignees. The report provides actionable intelligence supporting:

• Intellectual property strategy
• R&D prioritisation
• Competitive benchmarking
• Technology scouting
• Licensing evaluation
• Partnership assessment
• Investment analysis
• Market entry planning
• Portfolio expansion strategy

Research Methodology for the Molecular Diagnostics Platforms Patent Landscape Analysis

The study searches patent records from the USPTO, the European Patent Office, the China National Intellectual Property Administration, the Japan Patent Office and WIPO PATENTSCOPE. Queries combine keyword strings with CPC classes C12Q 1/68 and C12Q 1/6844 for nucleic acid detection, B01L 3/00 for microfluidic devices, and G01N 35/00 for automated analysers.

Results are screened by title, abstract and claim review to exclude research-only and non-diagnostic filings. Documents are consolidated into simple patent families, and assignee names are harmonised across subsidiaries and acquisitions.

The market side draws on regulatory databases such as FDA 510(k) and premarket approval records, company annual reports, clinical trial registries, WHO guidance and peer-reviewed literature. Patent counts are rounded estimates drawn from the search dataset.

Related Reports

Molecular Diagnostics Market

Infectious Disease Molecular Diagnostics Market

Molecular Diagnostics Patent Landscape Report